Investment Rating - The report maintains a "Leading the Market-A" rating for the pharmaceutical industry [3] Core Views - The global VC&PE investment and financing in innovative drugs showed a temporary decline in August 2024, but the overall trend has been improving since the beginning of 2024 [1][9] - The US market has shown significant improvement in VC&PE investment and financing for innovative drugs, particularly in 2024Q2 [2][12] Annual Perspective - In 2024H1, global VC&PE investment and financing in innovative drugs improved, with the US showing a notable recovery: global investment decreased by 2.35% YoY, while US investment increased by 15.51% YoY, marking a 27.73 and 54.88 percentage point improvement respectively compared to the same period last year [2][10] Quarterly Perspective - In 2024Q2, the US market saw a significant improvement in VC&PE investment and financing for innovative drugs: global investment decreased by 6.55% YoY, US investment increased by 22.45% YoY, and domestic investment decreased by 45.11% YoY [3][12] Monthly Perspective - In August 2024, global VC&PE investment and financing in innovative drugs experienced a temporary decline: global investment decreased by 33.01% YoY, US investment decreased by 31.18% YoY, and domestic investment decreased by 64.18% YoY [3][14] Industry Performance - The pharmaceutical industry underperformed compared to the CSI 300 index, with relative returns of -3.3% over 1 month, -1.2% over 3 months, and -4.4% over 12 months [4]
医药产业链数据库之：创新药投融资，2024年8月全球创新药投融资暂时下滑，但2024年以来整体仍呈改善趋势
Guotou Securities·2024-09-09 13:03